Good analysis. Beyond what you have said, much of the heaviest weight for pricing is based on quality life years and that pricing is likely to go higher for indications not yet approved but being treated as IFRs. IFRs also would allow patients access to experimental treatment with Poly ICLC or other treatments because of the associated likelihood of documented increased benefit in use with murcidencel/DCVax-L. As you state, this allows for a broad real world data base to be developed for use with applications for label extensions. Best wishes.
Hi Slave1 You are quite confident that they are in label phase based on NICE letter that NWBO is not in a position to submit evidence . Won't the NICE say the same if they are still in RFI stage ?
Market Data 
Markets 
AI
